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Abstract
T cells are important mediators of autoimmune inflammation in relapsing remitting multiple
sclerosis (RRMS). Previous studies found that deferiprone, an iron chelator, suppressed disease
activity in a mouse model of multiple sclerosis, and inhibition of T cell proliferation was
implicated as a putative mechanism. The objective of the present study was to examine the effects
of deferiprone on suppressing in vitro responses of T cells from control and RRMS subjects.
Peripheral blood T cells were co-stimulated with anti-CD3 + anti-CD28 and cultured with or
without interleukin 2 (IL-2). Proliferating CD4+ T cells from control and RRMS subjects, cultured
with or without IL-2, decreased in response to 75 μM deferiprone, although the extent of
decreased proliferation of CD4+ T cells from RRMS subjects was less than for control subjects.
Proliferating CD8+ T cells from control subjects, cultured with or without IL-2, also decreased in
response to 75 μM deferiprone, and this decrease was seen in proliferating CD8+ T cells from
RRMS cultured with IL-2. CD4+CD25+ and CD8+CD25+ cells from control subjects, cultured
with or without IL-2, declined in 75 M deferiprone, but the decrease was smaller than for the
CD4+ and CD8+ proliferative responses. CD4+CD25+ and CD8+CD25+ cells from RRMS
subjects showed more variability than for control subjects, but CD4+CD25+ cultured with IL-2
and CD8+CD25+ cells cultured without IL-2 significantly declined in 75 μM deferiprone.
CD4+FoxP3+ and CD4+CD25+FoxP3+ cells tended to remain constant or increase. In summary,
deferiprone induced declines in proliferative responses at a dosage that is within peak serum
pharmacological concentrations.
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1. Introduction
There is a scarcity of efficacious treatment options for disease exacerbations during
relapsing-remitting multiple sclerosis (RRMS). The most common intervention is a steroid,
e.g., methylprednisolone delivered via the oral or intravenous route. Corticosteroids hasten
recovery from a relapse [1], but do not lower the rate of new exacerbations or lessen the
progression of long-term disability [2]. Side effects from corticosteroid therapy include
hyperglycemia, hypokalemia, ankle swelling, facial flushing, insomnia, psychiatric changes,
bone loss and gastric disturbances [1,3–5].
For patients that do not respond or who cannot tolerate corticosteroids, other interventions
can be considered such as plasma exchange or intravenous immunoglobulin [5,6]. However,
these treatments are very expensive and time consuming, and have limited effectiveness [1].
The lack of efficacious secondary treatment options, the occurrence of side effects
attributable to corticosteroids, and the failure of corticosteroids to lessen subsequent relapses
or alter the disease progression, establish a need for new interventions for disease
exacerbations. The animal model experimental autoimmune encephalomyelitis (EAE) is
commonly used to test compounds for possible usefulness in MS. This strategy has resulted
in the development of several compounds that are now standard treatments for RRMS [7].
EAE studies often utilize an experimental design that entails the administration of a test
compound prior to the onset of EAE clinical signs. However, this design is not optimal for
testing a compound for use during disease exacerbation since early administration of the
compound may interfere with the development of disease rather than suppressing ongoing
clinical signs [8]. When the drug deferiprone was tested in the SJL mouse model of EAE, it
was administered after the onset of clinical signs [9]. This drug suppressed disease activity
in a pronounced manner at a time when clinical signs are normally rapidly advancing.
Further tests showed that deferiprone suppressed the proliferation of activated T cells [9],
which are key mediators of pathogenesis in EAE and RRMS [10,11].
Deferiprone is an orally available iron chelator that causes immunomodulation in patients
experiencing immunostimulation due to transfusion iron overload [12]. In this population,
levels of CD8 lymphocytes, TNFα, and IL-2 were elevated prior to treatment, and returned
to normal levels following deferiprone administration. The level of the anti-inflammatory
cytokine, IL-10, increased after treatment but remained within the normal range.
Furthermore, deferiprone was also found to suppress oxidative damage in this patient
population [13]. The action of deferiprone on immune cells from MS subjects is unknown.
The objective of the present studies was to examine the effects of deferiprone on T
lymphocytes from RRMS and healthy control subjects.
2. Materials and Methods
2.1. Human subjects
This study was approved by the Human Subjects Committee of the University of Kansas
Medical Center. Patients and control subjects were recruited at the University of Kansas
Medical Center Multiple Sclerosis Clinic, and informed consent was obtained. Patients had a
definite diagnosis of MS, as defined by the revised McDonald Criteria [14], and were
classified as having RRMS according to the Lublin-Rheingold classification [15]. T cells
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from seven female patients with RRMS (age range 38–57; mean age 49.0 +/− 2.7 standard
error of the mean) and four female and one male healthy controls (age range 24–51; mean
age 39.6 +/− 5.1) were evaluated. All RRMS patients but one was in remission at the time of
blood collection, and four of seven were on a MS disease modifying therapy, i.e., interferon
beta-1a or 1b, but none were receiving a corticosteroid.
2.2. Antibodies and reagents
PE-Cy™5 mouse anti-human CD4, PE-Cy™7 mouse anti-human CD8, APC-Cy™7 mouse
anti-human CD25 and Alexa Fluor 647 mouse anti-human FoxP3 were obtained from BD
BioSciences, San Jose, CA. Anti-human CD3 was obtained from BD BioSciences and
eBioscience, San Diego, CA. Anti-human CD28 was obtained from Ancell, Bayport, MN.
Live/dead fixable violet stain and 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester
(CFSE) were obtained from Invitrogen, Carlsbad, CA. Deferiprone was kindly supplied by
ApoPharma, Inc., Toronto, ON. EasySep® T cell Enrichment Cocktail Magnetic
Nanoparticle separation system was obtained from Stemcell Technologies, Vancouver, BC.
Fetal Bovine Serum (FBS), interleukin 2 (IL-2), L-glutamate, Penicillin-Streptomycin, and
RPMI 1640 medium were obtained from Sigma-Aldrich, St. Louis, MO. Ficoll-Paque
PLUS™ was obtained from Amersham Biosciences, Uppsala, Sweden.
2.3. Blood collection, leukocyte separation, and cell plating
Blood was collected in green top tubes containing heparin, stored at room temperature, and
processed within ~24 h of collection. Leukocytes were separated from the whole blood by
Ficoll-Paque PLUS™ density centrifugation followed by negative T-cell selection using an
EasySep® T cell Enrichment Cocktail Magnetic Nanoparticle separation system. After
separation, cells were washed with phosphate buffered saline (PBS), resuspended in PBS
with 0.1% FBS, incubated in 1.5 μM CFSE in dimmed lighting for 8 min at room
temperature, diluted with an equal volume of FBS, incubated for an additional 10 min at 37
°C in dimmed lighting, washed with PBS + 2% FBS and resuspended in RPMI 1640
medium, 10% FBS, 1% Penicillin-Streptomycin, 1% L-glutamate.
Cells were plated at 1.5–2 × 105 cells/well in 96 well Falcon Microtiter plates that were
precoated with 1 μg/mL anti-human CD3 and 5 μg/mL anti-human CD28 antibodies in PBS.
Cells were cultured for 4 days with 0 – 200 μM deferiprone in the presence or absence of
100 IU IL-2/well.
2.4. Cell staining and flow cytometry
Following 4 days of culture, cells were stained with PE-Cy5 mouse anti-human CD4, PE-
Cy7 mouse anti-human CD8, APC-Cy7 mouse anti-human CD25, and live/dead fixable
violet stain followed by Alexa Fluor 647 mouse anti-human FoxP3 and fixation with 1%
paraformaldehyde in PBS. Approximately 1.5 × 104 cells/well were analyzed with a BD
LSRII Flow Cytometer, using FACSDiva software.
2.5. Data analysis and statistics
Dot plots and histograms representing the number of mitoses per gated cells were prepared
using FlowJo software (Ashland, OR). Ratios were prepared for data obtained for
deferiprone divided by data obtained for vehicle, which was the complete culture media.
Measurements of area under the curve were calculated from ratio data collected over a range
of 25–100 μM deferiprone concentrations for each subject (controls, n = 5; RRMS, n = 7,
one subject's values utilized an extrapolated line for area calculation). Comparisons of ratios
between responses at 75 μM deferiprone and vehicle within a subject group utilized the one-
tailed Wilcoxon matched-pairs signed-rank test (controls, n = 5; RRMS, n = 6 as one RRMS
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subject didn't receive 75 μM deferiprone). Comparisons of ratio values at 75 μM deferiprone
between subject groups utilized a one-tailed Wilcoxon two sample test. Analysis of areas
under the curve utilized a one-tailed Student t-test. Significance was set at p ≤ 0.05 for all
tests.
3. Results
3.1. Proliferative responses of CD4+ and CD8+ T cells, in the presence of T cell receptor
(TCR) co-stimulation, evaluated over a range of deferiprone concentrations
Absolute raw data values displayed variable results between human subjects as expected.
Due to this inherent variability, each subject served as their own control to normalize the
data so that comparative analyses between populations, i.e., control subjects vs. RRMS
subjects, could be made. Thus, data obtained in the presence of deferiprone were divided by
data obtained in the absence of deferiprone (vehicle control) where a value below 1
represented a decreased response relative to vehicle.
Proliferating CD4+ and CD8+ T cells from control subjects, cultured in the presence or
absence of IL-2, had reached values of < 0.14 (response to deferiprone divided by response
in vehicle) at 75 μM deferiprone (p = 0.031 with or without IL-2) and the ratios were
generally unchanged with increasing deferiprone concentrations up to 150 μM (Fig. 1A). In
contrast, the ratios of proliferating CD4+cells from RRMS subjects had a ratio of >0.4 at 75
μM deferiprone in either the presence (p = 0.016) or absence (p = 0.031) of IL-2, and at
higher concentrations of deferiprone up to 150 μM the ratios typically continued to drop.
Proliferating CD8+ cells from RRMS subjects (Fig. 1B) showed more variability than
proliferating CD4+ cells, but significant decreases were observed at 75 μM for RRMS
subjects with IL-2 (p = 0.031). At 75 μM, significant differences were observed between
RRMS and control subjects for proliferating CD4 cells cultured with (p= 0.041) or without
(p = 0.009) IL-2, but did not reach significance for proliferating CD8 cells (p = 0.063 with
or without IL-2).
For proliferating CD4+ or CD8+ T cells cultured with or without IL-2, the area under a line
connecting the data points at 25, 50, 75 and 100 μM did not show a dependency on the
subject's age. Although the areas under the curve were greater for RRMS subjects compared
to control subjects (Fig. 1C,D), the differences failed to reach statistical significance. T cells
from RRMS patients receiving a disease modifying therapy of interferon beta-1a or 1b did
not show greater resistance to inhibition of proliferation by deferiprone compared to RRMS
patients not receiving this intervention.
3.2. The effect of deferiprone on net change of CD4+ and CD8+ T cells in the presence of
TCR co-stimulation
In order to determine whether the decreases in proliferation (Fig. 1) were due to net changes
in viable cells, CD4+ and CD8+ T cells from control and RRMS subjects were compared for
effects on cell expansion during TCR co-stimulation in the presence or absence of IL-2 and
under treatment with varying concentrations of deferiprone. The viable cell ratios
(deferiprone/vehicle) remained relatively constant over the range of deferiprone
concentrations for both control and RRMS CD4+ T cells (Fig. 2A), suggesting no overt
toxicity of the drug resulting in cell death. There was a tendency for a small decrease of the
viable ratios (deferiprone/vehicle) of CD8+ cells at higher concentration of deferiprone, in
the presence or absence of IL-2, for T cells from control and RRMS subjects (Fig. 2B).
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3.3. The effect of deferiprone on sustained responses of CD4+CD25+ and CD8+CD25+ T
cells in the presence of TCR co-stimulation
Expression of the IL-2 receptor subunit CD25 is an early index of T cell activation and
activated T cells promote immune activity in RRMS. Elevated expression of CD25 in
conjunction with FoxP3 indicates regulatory T cells which can oppose immune activity in
RRMS.
The ability of deferiprone to influence proliferation by CD25+CD4+ or CD25+CD8+ T cells
from control and RRMS subjects was examined in the presence or absence of IL-2. The
proliferation index of CD4+CD25+ cells was decreased at 75 μM for T cells from control
subjects cultured in the presence or absence of IL-2 (p = 0.031) but generally remained
above 0.4 (response to deferiprone divided by response to vehicle) even at higher
deferiprone concentrations (Fig. 3A). For RRMS subjects there was more variability, but the
ratios of CD4+CD25+ cells did reach significance at 75 μM with IL-2 (p = 0.031), and the
ratios remained above 0.4 at higher deferiprone concentrations (Fig. 3A). This suggests that
the proliferating CD4+CD25+ T cell subset (Fig. 3A) was more resistant to inhibition by
deferiprone than the total CD4+ subset (Fig. 1A). The ratio of proliferating CD8+CD25+
was decreased at 75 M for RRMS subjects without IL-2 (p = 0.016) and for control subjects
with or without IL-2 (p = 0.031) (Fig. 3B).
3.4. The effect of deferiprone on proliferative responses of CD4+CD25+ T cells in the
presence of TCR co-stimulation
Proliferating responses to TCR co-stimulation through anti-CD3 + anti-CD28 were
evaluated in T cells from control and RRMS subjects exposed to 0 or 75 μM deferiprone
(Fig. 4). Control and RRMS T cells cultured in the absence of deferiprone showed activation
(CD25 fluorescent intensity ≥3 × 102) and abundant proliferation. In the presence of 75 μM
deferiprone, control and RRMS T cells had a greatly reduced level of proliferation compared
to vehicle (Fig. 4).
3.5. The effect of deferiprone on proliferative responses of CD4+FoxP3+ and
CD4+CD25+FoxP3+ T cells in the presence of TCR co-stimulation
The transcription factor FoxP3 is considered to represent a primary subset of Treg. This
subset is considered to be characterized phenotypically as CD4+CD25+Foxp3+. This subset
was examined for responses to various concentrations of deferiprone. There was a high
degree of variability for CD4+FoxP3+ and CD4+CD25+FoxP3+ T cells from control and
RRMS subjects, but there was an overall tendency for an increase in the ratios with
concentrations of deferiprone ≥ 25 μM (Fig. 5) principally in the presence of exogenously
added IL-2. This is consistent with other findings that inducible Treg can be expanded in
number in response to co-stimulation through anti-CD3 + anti-CD28 in the presence of IL-2
[16]. Interestingly, this apparent Treg subpopulation was relatively resistant to inhibition by
deferiprone in contrast to the bulk of the CD4+ T cells. In addition, it should be noted that
this phenotype does not conclusively identify these cells as Treg without a test of inhibitory
activity.
4. Discussion
Deferiprone is a bidentate iron chelator that forms a 3:1 complex with iron. The drug is
rapidly absorbed from the GI tract with peak serum concentrations within 1 h in fasted
patients and 2 h in fed patients. The typical dosage for patients with thalassemia major is 25
mg/kg body weight three times per day for a daily dose of 75 mg/kg body weight. A dose of
25 mg/kg resulted in peak serum concentrations of 85 and 126 μM in the fed and fasting
state, respectively [17]. Deferiprone has access to CNS cells since it crosses the blood-brain
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barrier [18], and it has been used in a small clinical trial to treat Friedreich ataxia in humans
[19].
Data in the present study found that an in vitro deferiprone concentration of 50 μM resulted
in suppression of proliferating CD4+ or proliferating CD8+ T cells from control subjects
and a dose of 75 μM resulted in maximum suppression. Since the levels of IL-2 producing T
cells are increased in acute MS compared to quiescent MS [20], it is likely that T cells will
be exposed to elevated levels of IL-2 during an exacerbation, and thus, it is of interest to
examine the effects of IL-2. IL-2 may have provided a small delay to the decrease in
proliferation at 50 μM, but the levels were comparable at 75 μM deferiprone. Greater
deferiprone concentrations were required for maximum suppression of proliferation of
CD4+ and CD8+ cells in RRMS subjects, but a concentration of 50 μM gave signs of
suppression and ~50% suppression was achieved at 75 μM in this group. Comparable levels
of suppression were observed with or without IL-2 at 75 μM. Thus, it is possible that the
standard dosage of deferiprone used to treat iron overload in thalassemia patients could blunt
proliferative responses in T cells from MS subjects during a disease exacerbation raising the
possibility that it might have therapeutic value. In support of this, oral administration of
deferiprone, 150 mg/kg twice per day, to mice with active EAE resulted in a stabilization of
disease within 1 day while EAE animals administered vehicle continued to get worse [9].
This dosage favors a deferiprone:iron ratio > 3, which is required for proper chelation. When
the human equivalent dosage is calculated based on the dosage used in mice [21], a dosage
of ~24 mg/kg twice per day is obtained, which is within the standard dosing regimen for
thalassemia in humans. Deferiprone (250 μM) was also shown to inhibit proliferation of
cultured, co-stimulated mouse splenocytes [9], and when it was administered to thalassemia
major patients it lowered elevated levels of CD8+ cells as well as serum levels of TNFα and
IL-2 to normal values [12].
Deferiprone is thought to act by interrupting iron replenishment of ribonucleotide reductase,
which has two ferric ions that undergo spontaneous removal [22]. Hence, deferiprone may
inhibit T cell proliferation by disrupting the function of ribonucleotide reductase, which
catalyzes the reduction of ribonucleotides to deoxyribonucleotides that are required for DNA
synthesis. Reducing DNA synthesis is thought to induce cytostasis of activated T and B
cells, and this mechanism is exploited by other drugs, e.g., the dihydroorotate
dehydrogenase inhibitor leflunomide and its active metabolite teriflunomide, that are used
for the treatment of autoimmune disorders such as rheumatoid arthritis and possibly MS
[23].
The IL-2 receptor subunit CD25 is expressed by activated effector T cells and in conjunction
with FoxP3 it is also expressed in Treg cells. The former are pro-pathogenic and the latter
help to ameliorate or control disease activity in MS and other autoimmune diseases. Thus,
CD25 is involved with heterogeneous responses. In MS, an enhanced expression of CD25
on CD4+ cells is positively correlated with disease activity [24]. The presence of
deferiprone decreased proliferative responses by CD4+CD25+ or CD8+CD25+ cells. The
profile of decreased proliferative responses was similar to that observed for proliferating
CD4+ or proliferating CD8+ cells, except that the maximum amount of suppression was less
for the CD4+CD25+ or CD8+CD25+ cells. This incomplete reduction may be due, in part,
to the preservation or increase in Treg cells that express CD4 and CD25 as well as FoxP3.
Indeed, although there was a high degree of variability and much fewer labeled Treg cells
than for proliferating T cells, in general, there was preservation or an increase in
CD4+FoxP3+ and CD4+CD25+FoxP3+ cells that was associated with deferiprone
concentrations ranging from 50 – 100 μM, although further study of a larger sample size is
necessary to establish this finding. Furthermore, it is important to note that the intervention
or disease status can affect Treg activity in MS [25,26]. If additional studies show that
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deferiprone does increase activity of Treg cells, then deferiprone might exert a salubrious
effect during exacerbation of symptoms. Further characterization of the activation state of
the Treg in response to deferiprone is warranted.
The most common negative side effects of deferiprone administration include
gastrointestinal symptoms (i.e., abdominal pain, nausea and vomiting) and joint symptoms
(i.e., pain or swelling). The most serious adverse effect is agranulocytosis, but apparently it
is not dose dependent. Milder neutropenia can also be present. Blood counts are
recommended on a weekly basis to monitor for the development of agranulocytosis or
milder neutropenia. For MS subjects, further toxicity and immunological studies that
investigate possible interactions of deferiprone with MS disease modifying therapies might
be warranted.
In summary, deferiprone has been shown to lower proliferation of CD4+ and CD8+ cells.
Proliferation is associated with generating an immune response which can be deleterious in
an autoimmune disease like MS. Although these data support further study of deferiprone in
MS, negative side effects attributable to the drug indicate that only carefully designed
studies that emphasize safety should be pursued in future investigations.
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• Deferiprone is a potential treatment for relapsing remitting multiple sclerosis
• Deferiprone was applied to T cells collected from RRMS or control subjects
• T cell proliferation decreased in response to pharmacological levels of
deferiprone
• CD4+CD25+ and CD8+CD25+ cells declined in the presence of deferiprone
• The findings are relevant for studies on the role of this drug in RRMS subjects
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Proliferation of CD4+ and CD8+ T cells as measured by analyzing CFSE from control and
RRMS subjects in the presence of deferiprone. The deferiprone/vehicle (complete culture
media without drug) ratio was measured for control or RRMS cells cultured with or without
IL-2. A) CD4+ proliferating and B) CD8+ proliferating cells (error bars = SEM). For each
subject, the area under the lines over 25–100 μM deferiprone concentrations with or without
IL-2 was determined and plotted according to the subject's age; C) CD4+ proliferating and
D) CD8+ proliferating cells. There was not a statistically significant difference between the
area under the curve for RRMS and control subjects (one tailed Student t-test, significance at
p ≤ 0.05). Plots of mean ± s.e. for each group (triangle – control subject; circle – RRMS
subject; unfilled symbol – without IL-2; filled symbol – with IL-2). N=5 control subjects
(cells from 1 subject had 5 μM as the lowest deferiprone concentration); n=7 RRMS
subjects (1 subject was treated with a limited deferiprone profile: 0, 0.5, 1, 5, 10, 50, 100,
200 μM, and its area under the curve was generated from an extrapolated line. Also, CD4+ T
cells treated with IL-2 from one subject had 10 μM as the lowest deferiprone concentration).
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Effect of deferiprone on net changes in the percentage of viable CD4+ and CD8+ T cells. T
cells were cultured with TCR co-stimulation (e.g., anti-CD3 + anti-CD28) in the presence of
varying concentrations of deferiprone. The ratio of data obtained at different concentrations
of deferiprone vs. vehicle (complete culture media without drug) was calculated for control
or RRMS cells cultured with or without IL-2. A) CD4+ and B) CD8+ cells (viability
determined by exclusion of live/dead fixable violet stain, and then gated for live cells). Plots
of mean ± s.e. for each group (triangle – control subject; circle – RRMS subject; unfilled
symbol – without IL-2; filled symbol – with IL-2). N=5 control subjects (cells from 1
subject had 5 μM as the lowest deferiprone concentration); n=7 RRMS subjects (1 subject
was treated with a limited deferiprone profile: 0, 0.5, 1, 5, 10, 50, 100, 200 μM).
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Effect of deferiprone on CD4+CD25+ and CD8+CD25+ T cells. The modulation of double
positive CD4+CD25+ or CD8+CD25+ T cells from control and RRMS subjects was
analyzed using a ratio of proliferating (CFSE) A) CD4+CD25+ or B) CD8+CD25+ T cells
in the presence of deferiprone divided by the equivalent cell populations cultured in the
vehicle (complete culture media without drug). At 75 μM deferiprone, less proliferation was
observed for RRMS subjects (CD4+CD25+ with IL-2; CD8+CD25+ without IL-2) and for
control subjects (CD4+CD25+ or CD8+CD25+ with or without IL-2). Thus, deferiprone
mitigates the normal proliferation of T cells upon TCR co-stimulation regardless of
mitogenic co-stimulation (presence or absence of IL-2). Plots of mean ± s.e. for each group
(triangle – control subject; circle – RRMS subject; unfilled symbol – without IL-2; filled
symbol – with IL-2). N=5 control subjects (cells from 1 subject had 5 μM as the lowest
deferiprone concentration); n=7 RRMS subjects (1 subject was treated with a limited
deferiprone profile: 0, 0.5, 1, 5, 10, 50, 100, 200 μM).
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Raw data illustrating the effects of deferiprone on proliferating CD4+ cells. A) CD4+ cells
were cultured from a control or RRMS subject in the absence (0 μM) or presence (75 μM) of
deferiprone without IL-2. Gating was performed on live cells that were CD4+. CFSE and
CD25 intensities were plotted on the x and y axes, respectively. Proliferating cells appear to
the left of 103 CFSE staining. As revealed in the upper left quadrants, 75 μM deferiprone
decreased the proliferation of CD4+CD25+ T cells from control and RRMS subjects. B)
Histograms of CFSE fluorescence with gating of live CD4+CD25+ cells in A. The X axis is
CFSE level of fluorescence and the Y axis is number of cells. As revealed in the lower left
boxes, 75 μM deferiprone greatly decreased the proliferation of CD4+CD25+ T cells.
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Responses of Treg from control and RRMS subjects in the presence of deferiprone with or
without IL-2. A) CD4+FoxP3+ and B) CD4+CD25+FoxP3+ cells. Plots of mean ± s.e. for
each group (triangle – control subject; circle – RRMS subject; unfilled symbol – without
IL-2; filled symbol – with IL-2). N=5 control subjects (cells from 1 subject had 5 μM as the
lowest deferiprone concentration); n=7 RRMS subjects (1 subject was treated with a limited
deferiprone profile: 0, 0.5, 1, 5, 10, 50, 100, 200 μM, and the 10 μM concentration for
CD4+CD25+FoxP3+ was missing for 1 RRMS subject).
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